Institutional investors and equity analysts are invited to a research and development day in New York on Sept. 24 sponsored by Fibrocell Science of Exton.
The autologous cell therapy company is developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Presentations by key opinion leaders will include the company’s lead orphan disease program that uses genetically-modified autologous fibroblasts, developed in collaboration with the synthetic biology firm Intrexon Corporation, to treat recessive dystrophic epidermolysis bullosa, a debilitating, genetic skin disease.
Updates will also be presented on two Phase II clinical trials for azficel-T, Fibrocell’s proprietary autologous fibroblast technology for vocal cord and restrictive burn scarring.
Attendance at R&D Day is by invitation only by contacting Susan Noonan at [email protected]. Presentations will be webcast live here.
